**Serial Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness**

Peter A. McCullough, MD, MPH, Marlies Ostermann, MD, Lui G. Forni, MD, Azra Bihorac, MD, Jay L. Koyner, MD, Lakhmir S. Chawla, MD, Jing Shi PhD, J. Patrick Kampf, PhD, Paul McPherson, PhD, John A. Kellum MD, for the SAPPHIRE Investigators

**Supplemental Tables**

**Table S1**. Potentially nephrotoxic drugs considered

|  |
| --- |
| **Drug name / category** |
| Angiotensin-converting enzyme inhibitors |
| Angiotensin II receptor blockers |
| Acyclovir |
| Aminoglycosides |
| Amoxicillin with clavulanate |
| Calcineurin inhibitors |
| Cefepime |
| Nonsteroidal anti-inflammatory drugs |
| Phenytoin |
| Piperacillin with tazobactam |
| Vancomycin |

**Table S2**. Baseline patient characteristics for patients with at least one [TIMP-2]•[IGFBP7] > 0.3 and by number of consecutive [TIMP-2]•[IGFBP7] > 2.0.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | Patients with[TIMP-2]•[IGFBP7]>0.3N=410 | Three Consecutive[TIMP-2]•[IGFBP7]≤2.0N=314 | One Consecutive[TIMP-2]•[IGFBP7]>2.0N=66 | Two Consecutive[TIMP-2]•[IGFBP7]>2.0N=12 | Three Consecutive[TIMP-2]•[IGFBP7]>2.0N=18 | p-value |
| Male | 256 (62%) | 195 (62%) | 41 (62%) | 7 (58%) | 13 (72%) | 0.87 |
| Age | 64 (53-74) | 65 (53-74) | 63 (54-74) | 68 (57-79) | 68 (52-74) | 0.77 |
| Race |  |  |  |  |  | 0.11 |
| White or Caucasian | 334 (81%) | 249 (79%) | 60 (91%) | 11 (92%) | 14 (78%) |  |
| Black or African American | 39 (10%) | 32 (10%) | 3 (5%) | 0 (0%) | 4 (22%) |  |
| Other or Unknown | 37 (9%) | 33 (11%) | 3 (5%) | 1 (8%) | 0 (0%) |  |
| Reason for ICU Admission |  |  |  |  |  |  |
| Cardiovascular | 128 (31%) | 97 (31%) | 21 (32%) | 3 (25%) | 7 (39%) | 0.87 |
| Neurological | 38 (9%) | 28 (9%) | 5 (8%) | 3 (25%) | 2 (11%) | 0.24 |
| Sepsis | 77 (19%) | 53 (17%) | 16 (24%) | 3 (25%) | 5 (28%) | 0.27 |
| Respiratory | 182 (44%) | 139 (44%) | 27 (41%) | 6 (50%) | 10 (56%) | 0.70 |
| Trauma | 31 (8%) | 24 (8%) | 5 (8%) | 0 (0%) | 2 (11%) | 0.85 |
| Surgery | 134 (33%) | 106 (34%) | 22 (33%) | 2 (17%) | 4 (22%) | 0.54 |
| Other | 68 (17%) | 54 (17%) | 11 (17%) | 1 (8%) | 2 (11%) | 0.90 |
| Medical History |  |  |  |  |  |  |
| COPD | 102 (25%) | 88 (28%) | 8 (12%) | 2 (17%) | 4 (22%) | 0.04 |
| Cancer | 107 (26%) | 80 (25%) | 18 (27%) | 2 (17%) | 7 (39%) | 0.56 |
| Chronic kidney disease | 34 (8%) | 26 (8%) | 2 (3%) | 2 (17%) | 4 (22%) | 0.03 |
| Liver disease | 20 (5%) | 12 (4%) | 6 (9%) | 1 (8%) | 1 (6%) | 0.17 |
| Heart failure | 68 (17%) | 51 (16%) | 11 (17%) | 2 (17%) | 4 (22%) | 0.88 |
| Coronary artery disease | 125 (30%) | 99 (32%) | 13 (20%) | 5 (42%) | 8 (44%) | 0.09 |
| Diabetes mellitus | 124 (30%) | 97 (31%) | 13 (20%) | 5 (42%) | 9 (50%) | 0.05 |
| Hypertension | 244 (60%) | 187 (60%) | 35 (53%) | 8 (67%) | 14 (78%) | 0.28 |
| Location prior to ICU admission |  |  |  |  |  | 0.50 |
| Emergency department | 158 (39%) | 124 (39%) | 25 (38%) | 4 (33%) | 5 (28%) |  |
| Operating room | 104 (25%) | 80 (25%) | 19 (29%) | 0 (0%) | 5 (28%) |  |
| Floor | 88 (21%) | 62 (20%) | 14 (21%) | 6 (50%) | 6 (33%) |  |
| Other ICU | 4 (1%) | 3 (1%) | 1 (2%) | 0 (0%) | 0 (0%) |  |
| Other Hospital  | 49 (12%) | 38 (12%) | 7 (11%) | 2 (17%) | 2 (11%) |  |
| Unknown | 7 (2%) | 7 (2%) | 0 (0%) | 0 (0%) | 0 (0%) |  |
| Mechanical ventilation at enrollment | 341 (83%) | 259 (82%) | 55 (83%) | 11 (92%) | 16 (89%) | 0.90 |
| Baseline serum creatinine (mg/dL) | 0.8 (0.6-1.1) | 0.8 (0.6-1.0) | 0.8 (0.7-1.3) | 1.1 (0.6-1.5) | 1.0 (0.8-1.5) | 0.05 |
| APACHE III score | 71 (52-94) | 68 (51-88) | 78 (53-102) | 101 (88-126) | 113 (97-136) | <0.001 |
| Non-renal APACHE III score | 61 (43-85) | 58 (42-79) | 70 (43-87) | 85 (69-102) | 98 (87-105) | <0.001 |

**Table S3.** Outcomes by number of consecutive [TIMP-2]•[IGFBP7] >0.3 (A) and 2.0 (B)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| A |   | Three Consecutive Negative (≤0.3) | One positive (>0.3) | Two Consecutive Positive (>0.3) | Three Consecutive Positive (>0.3) | p-value |
|  | All Patients | [TIMP-2]∙[IGFBP7]  | [TIMP-2]∙[IGFBP7] | [TIMP-2]∙[IGFBP7] | [TIMP-2]∙[IGFBP7] |
|   | N=530 | N=115 | N=128 | N=76 | N=211 |
| Stage 2-3 AKI within 7 days | 164 (30.9%) | 15 (13%) | 32 (25%) | 28 (36.8%) | 89 (42.2%) | <0.001 |
| RRT within 7 days | 25 (4.7%) | 4 (3.5%) | 3 (2.3%) | 3 (3.9%) | 15 (7.1%) | 0.169 |
| Death within 7 days | 33 (6.2%) | 5 (4.3%) | 5 (3.9%) | 6 (7.9%) | 17 (8.1%) | 0.330 |
| ICU length of stay (days) | 7 (4, 13.7) | 6.1 (3.6, 9.7) | 7.7 (4.1, 13.1) | 6.9 (3.0, 12.7) | 7.3 (4.1, 14.6) | 0.179 |
| Hospital length of stay (days) | 14.6 (8.7, 22.5) | 13.7 (8.3, 20.4) | 14.8 (9, 22.7) | 15.7 (9.2, 22.3) | 15 (8.6, 23.5) | 0.592 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| B | Patients with | Three Consecutive | One Consecutive | Two Consecutive | Three Consecutive | p-value |
|  | [TIMP-2]∙[IGFBP7]>0.3 | [TIMP-2]∙[IGFBP7]≤2.0 | [TIMP-2]∙[IGFBP7]>2.0 | [TIMP-2]∙[IGFBP7]>2.0 | [TIMP-2]∙[IGFBP7]>2.0 |
|   | N=410 | N=314 | N=66 | N=12 | N=18 |
| Stage 2-3 AKI within 7 days | 148 (36.1%) | 84 (26.8%) | 38 (57.7%) | 9 (75%) | 17 (94.4%) | <0.001 |
| RRT within 7 days | 21 (5.1%) | 7 (2.2%) | 4 (6.1%) | 3 (25%) | 7 (38.9%) | <0.001 |
| Death within 7 days | 28 (6.8%) | 19 (6.1%) | 3 (4.5%) | 1 (8.3%) | 5 (27.8%) | 0.003 |
| ICU length of stay (days) | 7.3 (4.1, 14.6) | 7 (4, 12.8) | 8.6 (4.2, 15.6) | 10.5 (6.5, 26.3) | 9.9 (5.1, 18.3) | 0.102 |
| Hospital length of stay (days) | 15.1 (8.9, 22.9) | 14 (8.4, 22.3) | 16.8 (10, 23.8) | 31.9 (29, 35.6) | 24.9 (23.1, 32.8) | 0.001 |

Continuous variables are reported as median (25th, 75th percentiles), and categorical variables as number (percent).

P values compare outcome distributions among patients grouped by number of positive biomarkers and are calculated by Kruskal-Wallis test for continuous variables and log-rank test for categorical variables.

**Table S4.** Time of onset of stage 2-3 AKI relative to urine samples collected for [TIMP-2]•[IGFBP7] measurement

|  |  |
| --- | --- |
|  | Time of onset of stage 2-3 AKI |
| Consecutive [TIMP-2]•[IGFBP7] > 0.3 | Within 1 week | Before enrollment | After enrollment | After first [TIMP-2]•[IGFBP7] > 0.3 | After second [TIMP-2]•[IGFBP7] > 0.3 | After third [TIMP-2]•[IGFBP7] > 0.3 |
| 0 (N=115) | 15 | 0 (0%) | 15 (100%) | N/A | N/A | N/A |
| 1 (N=128) | 32 | 5 (16%) | 27 (84%) | 23 (72%) | N/A | N/A |
| 2 (N=76) | 28 | 4 (14%) | 24 (86%) | 23 (82%) | 13 (46%) | N/A |
| 3 (N=211) | 89 | 17 (19%) | 72 (81%) | 70 (79%) | 47 (53%) | 34 (38%) |

|  |  |
| --- | --- |
|  | Time of onset of stage 2-3 AKI |
| Consecutive [TIMP-2]•[IGFBP7] > 2 | Within 1 week | Before enrollment | After enrollment | After first [TIMP-2]•[IGFBP7] > 2 | After second [TIMP-2]•[IGFBP7] > 2 | After third [TIMP-2]•[IGFBP7] > 2 |
| 0 (N=314) | 84 | 9 (11%) | 75 (89%) | N/A | N/A | N/A |
| 1 (N=66) | 38 | 9 (24%) | 29 (76%) | 22 (58%) | N/A | N/A |
| 2 (N=12) | 9 | 3 (33%) | 6 (67%) | 5 (56%) | 1 (11%) | N/A |
| 3 (N=18) | 17 | 5 (29%) | 12 (71%) | 10 (59%) | 4 (24%) | 1 (6%) |